John M Pagel Selected Research

DOTA-biotin (90Y-DOTA-biotin)

12/2020	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA.
1/2015	Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
11/2010	Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
7/2010	Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.
5/2009	A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
4/2006	A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
3/2003	Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John M Pagel Research Topics

Disease

42	Neoplasms (Cancer) 01/2022 - 03/2003
35	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 10/2012
32	Lymphoma (Lymphomas) 12/2021 - 03/2003
25	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2021 - 03/2006
23	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2021 - 03/2003
19	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 03/2003
17	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2005
13	Leukemia 12/2020 - 02/2008
12	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 06/2022 - 06/2008
11	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2016 - 12/2009
8	Residual Neoplasm 06/2022 - 11/2010
7	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 10/2007
6	Disease Progression 01/2022 - 06/2008
5	Neutropenia 12/2021 - 01/2015
5	Diarrhea 12/2021 - 01/2015
5	Myeloid Leukemia (Leukemia, Myelocytic) 12/2020 - 05/2007
4	Pneumonia (Pneumonitis) 01/2022 - 01/2015
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 01/2020
4	Multiple Myeloma 01/2022 - 02/2014
4	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 09/2008
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 03/2011
3	Colitis 01/2022 - 01/2015
3	Tumor Lysis Syndrome 12/2021 - 01/2018
3	Thrombocytopenia (Thrombopenia) 01/2021 - 01/2015
3	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2016 - 08/2010
2	Infections 10/2021 - 01/2020
2	AIDS-Related Complex (ARC) 01/2021 - 12/2019
2	Pathologic Complete Response 02/2015 - 11/2012
2	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2015 - 03/2003
2	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 06/2011 - 09/2005

Drug/Important Bio-Agent (IBA)

14	Rituximab (Mabthera)FDA Link 01/2022 - 05/2004
13	Radioisotopes (Radionuclides)IBA 01/2021 - 07/2006
12	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 01/2016
11	procaine isothiocyanate (PRIT)IBA 12/2020 - 06/2007
10	StreptavidinIBA 01/2015 - 04/2006
10	AntibodiesIBA 10/2012 - 03/2003
9	ibrutinibIBA 01/2022 - 01/2016
9	acalabrutinibIBA 01/2022 - 01/2016
9	fludarabineIBA 01/2021 - 12/2009
9	Monoclonal AntibodiesIBA 01/2020 - 05/2004
9	Biotin (Vitamin H)FDA Link 01/2015 - 03/2003
8	venetoclaxIBA 12/2021 - 01/2016
8	Proteins (Proteins, Gene)FDA Link 12/2020 - 04/2006
7	Chimeric Antigen ReceptorsIBA 06/2022 - 09/2008
7	DOTA-biotin (90Y-DOTA-biotin)IBA 12/2020 - 03/2003
6	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 11/2012
6	Immunoconjugates (Immunoconjugate)IBA 10/2020 - 06/2007
5	idelalisibIBA 01/2021 - 03/2014
4	Phosphotransferases (Kinase)IBA 01/2021 - 10/2015
4	AntigensIBA 12/2019 - 06/2007
3	brexucabtagene autoleucelIBA 06/2022 - 01/2020
3	obinutuzumabIBA 01/2022 - 04/2015
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2022 - 01/2015
3	Chlorambucil (Leukeran)FDA Link 01/2022 - 04/2015
3	umbralisibIBA 12/2021 - 01/2021
3	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 04/2013
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 03/2006
3	FenretinideIBA 01/2017 - 05/2004
3	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2015 - 03/2003
3	Indicators and Reagents (Reagents)IBA 01/2015 - 06/2007
3	GalactosamineIBA 07/2010 - 07/2006
3	HLA-DR Antigens (HLA-DR)IBA 05/2009 - 06/2007
2	Phosphatidylinositols (Phosphatidylinositol)IBA 12/2021 - 01/2021
2	Transaminases (Aminotransferases)IBA 12/2021 - 01/2019
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2021 - 04/2015
2	duvelisibIBA 12/2020 - 11/2019
2	Bendamustine Hydrochloride FDA Link 11/2020 - 08/2014
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 12/2019
2	Iodine-131IBA 12/2019 - 09/2014
2	RetinoidsIBA 01/2017 - 10/2015
2	tositumomab I-131 (Bexxar)FDA Link 01/2016 - 12/2012
2	Clofarabine (Clolar)FDA Link 08/2015 - 04/2015
2	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 06/2015 - 08/2014
2	ibritumomab tiuxetan (Zevalin)FDA Link 02/2015 - 07/2011
2	TRU 016IBA 01/2015 - 02/2014
2	treosulfanIBA 04/2014 - 03/2011
2	Carboplatin (JM8)FDA LinkGeneric 04/2013 - 08/2010
2	Surface Antigens (Surface Antigen)IBA 05/2009 - 06/2007
2	AcetylgalactosamineIBA 05/2009 - 09/2007
2	Leukocyte Common Antigens (CD45 Antigen)IBA 01/2009 - 08/2008
2	AcidsIBA 09/2007 - 06/2007
2	CaspasesIBA 07/2005 - 05/2004
1	axicabtagene ciloleucelIBA 01/2022
1	vecabrutinibIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	pembrolizumabIBA 01/2022
1	dinaciclibIBA 01/2022

Therapy/Procedure

51	Therapeutics 01/2022 - 07/2005
30	Radioimmunotherapy 12/2020 - 03/2003
27	Cell Transplantation 01/2021 - 01/2005
14	Drug Therapy (Chemotherapy) 01/2022 - 09/2007
9	Stem Cell Transplantation 01/2022 - 04/2007
9	Homologous Transplantation 02/2015 - 07/2006
7	Immunotherapy 01/2021 - 05/2008
5	Transplantation 09/2014 - 06/2008
4	Radiotherapy 01/2015 - 09/2007
4	Hematopoietic Stem Cell Transplantation 05/2013 - 04/2007
3	Autologous Transplantation 01/2020 - 07/2006
2	Induction Chemotherapy 10/2021 - 06/2008
2	Consolidation Chemotherapy 01/2020 - 02/2015